AR122237A1 - Anticuerpos anti-sortilina y métodos para su uso - Google Patents
Anticuerpos anti-sortilina y métodos para su usoInfo
- Publication number
- AR122237A1 AR122237A1 ARP190101981A ARP190101981A AR122237A1 AR 122237 A1 AR122237 A1 AR 122237A1 AR P190101981 A ARP190101981 A AR P190101981A AR P190101981 A ARP190101981 A AR P190101981A AR 122237 A1 AR122237 A1 AR 122237A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- sortilin
- sortilina
- methods
- compositions
- Prior art date
Links
- 102100032889 Sortilin Human genes 0.000 abstract 3
- 108010014657 sortilin Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- -1 for example Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción hace referencia, en términos generales, a composiciones que incluyen anticuerpos, por ejemplo, monoclonales, quiméricos, madurados por afinidad, anticuerpos humanizados, fragmentos de anticuerpos, etc., que se unen específicamente a la proteína sortilina, por ejemplo, sortilina humana o sortilina de mamífero, y que tienen características funcionales mejoradas y/o potenciadas, y al uso de tales composiciones en la prevención, disminución del riesgo o tratamiento de un individuo que lo necesite.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862698007P | 2018-07-13 | 2018-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122237A1 true AR122237A1 (es) | 2022-08-31 |
Family
ID=83218695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101981A AR122237A1 (es) | 2018-07-13 | 2019-07-12 | Anticuerpos anti-sortilina y métodos para su uso |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR122237A1 (es) |
| MA (1) | MA48870B1 (es) |
-
2019
- 2019-07-12 MA MA48870A patent/MA48870B1/fr unknown
- 2019-07-12 AR ARP190101981A patent/AR122237A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA48870A (fr) | 2020-04-01 |
| MA48870B1 (fr) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
| CL2021003535A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019) | |
| CR20230170A (es) | ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485) | |
| CR20200566A (es) | Anticuerpos anti-sirpa y metodos de utilización de los mismos | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| CL2022000230A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
| MX2024010324A (es) | Metodos de uso de anticuerpos anti-trem2. | |
| AR122237A1 (es) | Anticuerpos anti-sortilina y métodos para su uso | |
| EA201992335A1 (ru) | Антитела против сортилина и способы их применения | |
| AR112401A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos | |
| AR119536A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения |